Speaker illustration

Professor Marcin Ufnal

AstraZeneca, Gothenburg (Sweden)

AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: ePosters in chronic heart failure - treatment 5

Thumbnail

Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 6

Thumbnail

ESC 365 is supported by